Xconomy

AUGUST 11, 2016

government has ambitious plans for a long-term health study with one million Americans, and one of the world’s most powerful tech companies has a big part to play, including the storage of all the data on its “cloud” servers. Those concerns are shared by the public. But they did not view tech companies as trustworthy stewards.

PMI 40

PMI Study Google Research 40

Xconomy

AUGUST 17, 2016

Histogen, a San Diego-based regenerative medicine company with technology for growing skin cells and related products, said it has raised $6 million from an affiliate of Huapont Life Sciences, a healthcare products company based in Chongqing, China. Histogen claims that HSC triggers stem cells in the scalp to form hair.

Invest 40

Invest San Diego Journal Technical Review 40

Xconomy

APRIL 22, 2020

Given the number of late-stage and mid-stage studies expected to report data in 2020—assuming they stay on track amid the COVID-19 pandemic—this could be a pivotal year for the field, said Isabelle de Cremoux, CEO and managing partner of Seventure Partners.

Class 138

Class Study Research Report 138

Xconomy

FEBRUARY 14, 2020

Post-marketing studies aim to identify side effects not observed in the first three phases of testing. This week, results of such a study led to the market withdrawal of weight-loss pill lorcaserin (Belviq). But the post-marketing study revealed a higher incidence of.

Study 77

Study Marketing San Diego Blogging 77

Xconomy

AUGUST 17, 2016

San Diego’s Avelas Biosciences , founded in 2009 to advance a fluorescing biologic agent intended to help surgeons differentiate cancerous tissue from healthy tissue, has completed a $20 million Series C round of venture funding. and San Diego’s Avalon Ventures. Carmine Stengone.

Avalon 40

Avalon San Diego Study Invest 40

Xconomy

JULY 27, 2018

Eisai and partner Biogen released the highly anticipated details of an Alzheimer’s disease study they had already deemed positive, after an initial failure. In one sense, the study was the success they have claimed. A high dose of the drug appeared to have a positive impact on patients, compared to placebo.

Study 64

Study Invest San Diego Venture Capital 64

Xconomy

MARCH 27, 2020

Fallout from the spread of COVID-19 infections led several companies to declare this week that they would stop enrolling patients in clinical trials or postpone studies that have not yet started. The coronavirus pandemic has made it nearly impossible.

Study 95

Study Resource Sites San Diego 95

Xconomy

FEBRUARY 28, 2020

Making changes in the midst of the study was a no-no. Clinical trials have historically hewn to a rigid format. A trial is designed, conducted according to that design, and then results are analyzed. In recent years, regulators have showed openness to clinical trial designs intended to make drug testing more efficient.

News 89

News Design Study Examples 89

Xconomy

AUGUST 22, 2016

In downtown San Diego, a private real estate company best known for its master-planned communities in suburban Southern California has posed some existential questions for regional tech hubs looking to build their own startup ecosystems. 101 West Broadway tower in downtown San Diego. John “J.T.”

Develop 40

Develop Development San Diego Startup 40

Xconomy

MAY 22, 2020

But Phase 1 clinical trials are small, and it’s unknown whether those early results can be replicated in larger studies. No major safety problems were reported and there were some indications that the injections elicited antibodies. Furthermore, Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Study 80

Study Report San Diego Blogging 80

Both Sides of the Table

APRIL 13, 2011

I owe ya’ a 20 minute call (or in person next time I’m in San Diego). Brad on blogging. How did you start blogging? “My A deep dive into the Foundry Group investment philosophy including an interesting discussion of their investing Themes. “… our lens is: Internet Software Companies anywhere in the U.S.

Venture Capital 288

Venture Capital Startup Technical Review Software Review 288

Xconomy

AUGUST 14, 2020

Four years after its microbiome therapy failed in a mid-stage study, the company reported early positive data from a pivotal test of its treatment for a type of gut infection. The road of drug development is rife with detours and disappointments but Seres Therapeutics showed this week that course corrections can work.

Study 63

Study Course Report Company 63

Xconomy

SEPTEMBER 6, 2019

In presenting clinical data from a Phase 3 study. If MedCo’s cholesterol-lowering drug inclisiran wins FDA approval, it will become the third entry in a new class of medicines that block a cholesterol-boosting protein called PCSK9. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Pricing 84

Pricing Class Study Marketing 84

Xconomy

FEBRUARY 22, 2019

Intercept (NASDAQ: ICPT ) reported interim data from a Phase 3 study showing its drug, obeticholic acid (OCA), reduced liver scarring in NASH patients. This week, one company, Intercept Pharmaceuticals, solidified its lead. But how much will being first to the finish line mean when all is said and done?

News 86

News Study Report San Diego 86

Xconomy

JANUARY 9, 2019

The Boston company, which counts diabetes drug giants Eli Lilly (NYSE: LLY ) and Novo Nordisk (NYSE: NVO ) among its investors and partners, says the capital will support Phase 3 studies of its device this year, and if all goes well, an application for FDA approval. Beta Bionics’s device is designed to mimic the role of.

Study 87

Study Design Capital Startup 87

Xconomy

JUNE 13, 2019

The new Series B round will give San Francisco-based BlackThorn—a startup spun out of the Scripps Research Institute in 2013—the backing to run human tests of two experimental treatments. The other, for autism, could start a Phase 1 study in 2020. Those plans. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Tool 78

Tool Study Research Startup 78

Xconomy

JUNE 21, 2018

The San Francisco company priced its IPO late Tuesday, selling 6.25 Eidos will use the cash to fund studies of AG10 , a drug in mid-stage testing for transthyretin (TTR) amyloidosis, a progressive and fatal condition caused by the. million shares at $17 each, which was on the high end of its projected $15 to $17 range.

Study 72

Study Startup Pricing Funding 72

Xconomy

DECEMBER 21, 2016

After years of research, frustration, hype, and millions (sometimes hundreds of millions) of dollars invested, a drug program boils down to the clinical data—usually from big, late-stage studies—that can sometimes make or break a company. [Editor’s note: Alex Lash and Frank Vinluan contributed to this report.]

Study 40

Study Report Research Invest 40

Xconomy

JANUARY 11, 2017

A recent study by EdSurge , an edtech information firm, shows venture funding for U.S. billion invested in 198 deals in 2015, according to EdSurge. education tech companies totaled $1.03 billion (across 138 deals) in 2016. Those numbers are down from the $1.45

Funding 40

Funding Education Venture Capital Study 40

Xconomy

APRIL 6, 2018

The FDA didn’t smile upon a big submission of depression studies from Alkermes, while those fighting liver disease got a mixed slate of data as a big medical conference looms. After the deals, we’ll move on to data. There were plenty of policy and drug-price headlines, Read more » Reprints | Share:

Study 55

Study Conference Pricing Marketing 55

Xconomy

AUGUST 1, 2016

Ionis (NASDAQ: IONS ) and its partner, Cambridge, MA-based Biogen (NASDAQ: BIIB ), this morning reported an interim look at an ongoing Phase 3 study of nusinersen—an RNA-based drug meant to help treat patients with SMA. Ionis will complete the ongoing Phase 3 studies before transitioning everything to Biogen.

Study 40

Study Research Statistics Help 40

Xconomy

NOVEMBER 11, 2016

The Nitto drug is in a Phase 1b study. —The FDA lifted a partial clinical hold , meanwhile, on a planned cell therapy study from Philadelphia and U.K.-based —IBM Watson Health and the Broad Institute have teamed up on a five-year, $50 million research project to study why tumors become resistant to cancer drugs.

Patents 87

Patents Study Pricing Technical Review 87

socalTECH

MARCH 17, 2009

has done is give you easy access to a domain, for free, and given you enormously valuable software that you can use for free, and which allow you to use the services you've been part of, invested in developing identities on, and allows you to create and promote that identity in a.mp Rob Farrow: The average user is a great case study for us.

Social Network 147

Social Network San Diego Sites Startup 147

Xconomy

SEPTEMBER 21, 2016

At Xconomy, we have seen growing investments in the sector—both in a rash of new agtech startups and by bigger players such Monsanto, Bayer Crop Sciences, and Syngenta. The annual AgTech Investment Report from AgFunderNews found that investment in agriculture and food-related technology startups alone hit $4.6

Newsletter 40

Newsletter Research Technology Equity 40

socalTECH

FEBRUARY 23, 2009

San Diego-based Newsforce (www.newsforce.com) is a startup which is looking to take advantage of the hunger of the newspaper and media business for revenue, and has created a product which takes press releases and commercial content, and inserts them onto news sites in "sponsored content" blocks. How are you backed?

News 124

News Advertising Press Sites 124

Xconomy

MAY 30, 2016

Lita Nelsen has seen it up close—and played a part in its evolution—from her studies there in the 1960s, to her business-school fellowship in the late 1970s, to her 30 years working in MIT’s Technology Licensing Office. MIT’s approach to nurturing entrepreneurship has changed a lot over the past 50 years.

Startup 67

Startup Compton Research Course 67

Xconomy

MAY 24, 2019

Patients, doctors, family members, and drug-price watchdogs continued to wait for the expected approval of Zolgensma , a Novartis (NYSE: NVS ) gene therapy for the rare inherited disease spinal muscular atrophy. Originally developed at a children’s hospital in Ohio , Zolgensma will be a litmus test for the nascent field.

Pricing 86

Pricing Marketing Develop Development 86

Xconomy

AUGUST 30, 2019

You might be camping, barbecuing, or sleeping on Monday. It’s Labor Day, after all. But in Paris, this cardiologist will be in a conference center, walking an audience through a slide deck packed with Phase 3 data for a new cholesterol-lowering drug, inclisiran. Inclisiran’s owner, the Medicines Co.,

Slides 80

Slides Conference Venture Capital Study 80

Xconomy

AUGUST 12, 2016

Lilly will continue the study, but the news puts distance between abemaciclib and two similar, rival cancer drugs from Pfizer (palbociclib (Ibrance)) and Novartis (ribociclib)). Both Pfizer and Novartis stopped Phase 3 trials of their drugs early because they were clearly benefitting breast cancer patients. In the U.S.,

Google 40

Google Technical Review News Research 40

Xconomy

APRIL 20, 2018

The biggest news this week was in oncology, hands down. Merck showed that its immunotherapy pembrolizumab (Keytruda) might become a common option for many patients newly diagnosed with advanced lung cancer, but the bigger picture is that the field is moving fast.

Pricing 52

Pricing News Report Develop 52

Xconomy

JUNE 30, 2017

There is no Obamacare replacement, at least not as of this writing. The Senate Republicans are fractured, with a handful of conservatives and moderates each giving a cold shoulder to their chamber’s version of healthcare reform, the Better Care Reconciliation Act.

Writing 56

Writing Report Artificial Inteligence San Diego 56

Xconomy

AUGUST 11, 2017

With President Trump holed up in New Jersey, rattling his saber at Kim Jong-un and Mitch McConnell and ignoring his own commission’s advice on the opioid crisis, there was still life sciences news from the nation’s capital.

Pricing 52

Pricing News Report Competition 52